Clin Lab. 2022 Jun 1;68(6). doi: 10.7754/Clin.Lab.2021.210706.
The aim of this study was to investigate the infection and antimicrobial resistance of Ureaplasma urealyticum (U. urealyticum) and Mycoplasma hominis (M. hominis) in patients with genital tract diseases in Jiangsu, China.
A total of 3,321 patients suspected with genital tract infectious diseases were enrolled in this study from September 2017 to September 2020. The Mycoplasma detection and antimicrobial susceptibility were tested using the commercially available Mycoplasma kit.
Among the 3,321 specimens tested, 1,503 (45.3%) were positive for Mycoplasmas, and the proportion of mono-infection of U. urealyticum is highest (79.5%). The overall infection rate has been increasing in the past 3 years. The positive rate in females (68.7%) was higher than in males (25.0%), and the main infection age group was 20 - 39 (81.2%). Besides, U. urealyticum and M. hominis displayed relative lower resistance rates to gatifloxacin, josamycin, minocycline, and doxycycline (6.0%, 6.5%, 3.1%, and 3.2%, respectively). However, the antimicrobial resistance rates to azithromycin, clindamycin, roxithromycin, sparfloxacin, and ofloxacin were relatively high (45.4%, 42.1%, 34.9, 36.0, and 65.5%, respectively). Antimicrobial resistance of U. urealyticum and M. hominis to these 14 drugs have been changing in the past 3 years.
In total, these preliminary data showed the prevalence and antimicrobial resistance status of U. urealyticum and M. hominis in patients suspected with genital tract infectious diseases, which has use for reference on both prevention and treatment of diseases caused by them.
本研究旨在调查中国江苏地区生殖道疾病患者解脲脲原体(U. urealyticum)和人型支原体(M. hominis)的感染和抗菌药物耐药情况。
2017 年 9 月至 2020 年 9 月,共纳入 3321 例疑似生殖道感染患者。采用商用支原体试剂盒进行支原体检测和药敏试验。
在 3321 份标本中,1503 份(45.3%)检测出支原体阳性,其中解脲脲原体的单感染率最高(79.5%)。过去 3 年来,总感染率呈上升趋势。女性(68.7%)的阳性率高于男性(25.0%),主要感染年龄组为 20-39 岁(81.2%)。此外,解脲脲原体和人型支原体对加替沙星、交沙霉素、米诺环素和强力霉素的耐药率相对较低(分别为 6.0%、6.5%、3.1%和 3.2%)。然而,对阿奇霉素、克林霉素、罗红霉素、司帕沙星和氧氟沙星的耐药率相对较高(分别为 45.4%、42.1%、34.9%、36.0%和 65.5%)。过去 3 年来,解脲脲原体和人型支原体对这 14 种药物的抗菌药物耐药性一直在变化。
这些初步数据显示了疑似生殖道感染患者中解脲脲原体和人型支原体的流行情况和抗菌药物耐药性,为疾病的预防和治疗提供了参考。